Now I have enough calibration data. Let me write the final review.

**Round 1 bracket**: [3.5, 4.5] — the paper is clearly above the 2.0–3.0 range (papers with severe writing quality or novelty issues) but below PEMs (4.75), which has stronger experimental execution and better-supported claims despite its own technical novelty limitations.

**Narrowing**: Comparing against PEMs (4.75, itemized), my paper's strengths are notably weaker (max +2.97 vs +5.30) and the two -5+ weighted weaknesses (CNN contradiction, 2-location evaluation) are heavier than PEMs' worst non-novelty items. The paper sits below PEMs, closer to the 4.0 level.

---

## Summary

This paper proposes HG-DCM, a framework that combines a neural network (which predicts compartmental model parameters) with a history-guided training strategy that pools data across biologically distinct pandemics (Ebola, SARS, Dengue, seasonal influenza) to improve cold-start forecasting of a novel pathogen. The core idea—that macroscopic disease dynamics driven by human behavior transfer across pathogens—is compelling. However, the experimental evaluation has significant gaps: the paper's own Table 2 contradicts its headline claims about the CNN baseline, the main benchmark against external methods uses only 2 locations, and the experimental design cannot isolate whether improvements come from cross-disease transfer or spatial pooling.

## Strengths

- **The core motivation is compelling and well-articulated (Section 1).** The observation that standard compartmental models treat each outbreak *de novo* while human epidemiologists draw on a mental library of historical curves is a genuinely insightful framing for cross-disease transfer learning. The argument that macroscopic spread dynamics are constrained by human behavior—independent of the specific pathogen—is a reasonable premise.

- **The design choice to remove BatchNorm (Section 2.1) is technically grounded.** The authors correctly identify that batch statistics differ across historically distinct pandemics, and removing BN layers is a clean, principled fix that reflects genuine thought about the problem.

- **The dataset construction represents real effort.** Assembling case data from COVID-19, Ebola, SARS, Dengue, and seasonal influenza from disparate sources into a unified dataset is a non-trivial contribution that could be a useful community resource if released.

- **The window-shift augmentation (Section 2.2) is sensible** for increasing sample diversity for historical pandemics without look-ahead bias, and the masking augmentation for the current pandemic is appropriate.

## Weaknesses

### Major

- **The paper's textual claims about the CNN ablation (Section 3.2.2) contradict its own Table 2.** The paper states: "Despite its greater expressiveness, CNN generally underperforms HG-DCM across all training horizons" and "The performance gap is largest in the early stage (2–4 weeks)." However, on **Mean MAE**, CNN beats HG-DCM at 2 weeks (15,600 vs 18,603) and decisively at 4 weeks (11,238 vs 110,452 — HG-DCM is ~10× worse). The claim holds on Median MAE but the text does not distinguish between metrics and makes a blanket assertion that is false for the primary reported metric at early windows. This is a factual error in a central result that undermines confidence in the paper's interpretation of its own evidence.

- **The main benchmark evaluation against external methods (Table 1) is conducted on only 2 locations** (United States and Massachusetts). While the paper acknowledges this ("limited data accessibility"), the abstract claims evaluation across "258 global locations." The ablation study (Table 2) does not specify its geographic coverage. Two high-income Western settings cannot support sweeping claims about cross-disease transfer for global pandemic forecasting. The paper needs either (a) evaluation across all available locations with at least simpler but universally deployable baselines, or (b) an explicit statement of how many locations Table 2 covers.

- **The experimental design conflates spatial pooling with cross-disease transfer.** HG-DCM trains across all locations and all pandemics simultaneously, while DELPHI fits models per location independently. Improvements could come from (a) cross-disease temporal transfer (the claimed mechanism), (b) spatial transfer across COVID-19 locations, or (c) the neural network's greater capacity. The T-DCM ablation (which excludes historical pandemic data) is intended to isolate (a), but the paper does **not clearly specify what data T-DCM trains on** — whether it uses only COVID-19 data from the evaluation location or pooled COVID-19 data across locations. Without this specification, the ablation cannot be properly interpreted, and the paper's central claim about cross-disease transfer is not convincingly evidenced.

### Minor

- **Table 1 reports only point estimates of MAE with no confidence intervals, standard errors, or statistical significance tests.** For a forecasting task on only 2 locations where variance is expected to be high, point estimates alone are insufficient evidence.

- **The historical dataset includes seasonal influenza from 2009–2023.** Influenza data from 2020–2023 falls within the COVID-19 era, when behavioral changes (masking, lockdowns) dramatically altered influenza dynamics. The paper does not discuss whether this introduces a contamination path where the model implicitly learns COVID-era patterns from influenza data.

### Trivial

None.

## Nice-to-Haves

- A counterfactual experiment that varies which pandemics are included in the historical set (e.g., exclude influenza entirely) would strengthen the causal claim about cross-disease transfer.
- An explicit comparison of HG-DCM against T-DCM trained on pooled COVID-19 data *without* historical pandemics would better isolate the cross-disease mechanism from spatial pooling.

## Removed Points

- *"The claim that HG-DCM consistently outperforms DELPHI is not supported by Table 2 at 6 and 8 weeks on median MAE"* — Moderated to minor/tone issue: the paper acknowledges 6-week median as "comparable" and on mean MAE HG-DCM does beat DELPHI everywhere. The 8-week median reversal is a minor overclaim, not a structural error.
- *Harsh critic's suggestion about discussing limitations of evaluation on COVID-19 only* — This is a reasonable observation but would require a held-out pandemic which the authors cannot obtain with available data. The paper scopes itself to COVID-19 evaluation, so this is scope creep.
- *Harsh critic's "data contamination" framing was kept but downgraded to minor* — The concern is valid, but the majority of influenza data (2009-2019) predates COVID, and the critic's framing as a "fatal" flaw was disproportionate.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Correct the textual claims about CNN in Section 3.2.2** to match what Table 2 actually shows. Distinguish between mean and median MAE when making comparative claims. Do not claim HG-DCM outperforms CNN at early stages on mean MAE when the data shows the opposite.

2. **Specify the geographic coverage** for every table. Table 2 needs an explicit statement of how many locations and which ones are included.

3. **Clarify T-DCM's training data composition**: does it train on COVID-19 data from only the evaluation location or from pooled locations? This is essential for interpreting the cross-disease transfer claim.

4. **Report results on a broader set of locations** against simpler baselines (e.g., T-DCM, per-location DELPHI, CNN) that can run everywhere, even if the sophisticated baselines cannot.

5. **Add confidence intervals or error bars** to at least the main results table.

6. **Discuss the COVID-era influenza data overlap** and whether excluding influenza data from 2020 onward changes results.

## Score and Decision

**Calibration Anchors Used:**
| Path | Avg Score | Round | Itemized | Comparison |
|------|-----------|-------|----------|------------|
| CpiOUOaqh3.md (Genetic Algorithm Epidemiology) | 2.00 | R1 | Yes | Much weaker: poor writing, no real baselines, very narrow scope. Our paper is clearly above this. |
| V83xzYnZ5q.md (Tuberculosis Forecasting) | 3.00 | R1 | No | Similar domain but less methodological depth. |
| DL7JWbdGr3.md (PEMs: Pre-trained Epidemic Models) | 4.75 | R1/R2 | Yes | Most similar paper: same problem (cross-disease transfer), stronger experimental execution, but also had novelty concerns. Our paper has weaker strengths and heavier evidential weaknesses. |
| vfHISoWo2m.md (Meta-Learning Dynamical Systems) | 4.00 | R2 | No | Different domain but comparable overall quality. |
| 4NhMhElWqP.md (DAM: Foundation Model for Forecasting) | 7.00 | R1 | Yes | Much stronger: thorough experiments, novel architecture, clean claims. Our paper does not approach this level. |

**Weighted-item comparison**: My draft's strongest positive items (+2.97, +2.92) are substantially weaker than PEMs' (+5.30, +3.34, +3.23). My draft's two strongest negative items (-5.05, -5.15) are comparable in weight to PEMs' strongest non-novelty negatives (-5.71 for missing baselines). The paper shares with PEMs the pattern of an interesting core idea undermined by insufficient evaluation and overclaiming, but my paper has the additional credibility issue of contradicting its own data.

**Round 1 bracket**: [3.5, 4.5]. Narrowed to 4.0 based on comparison with PEMs (4.75): my paper has weaker strengths and a factual error in its headline claims, placing it below the PEMs anchor.

**Score**: 4.0 — Borderline Reject.

The core idea is worth investigating and the dataset represents real effort, but the paper's own results contradict its central textual claims about the CNN baseline, the main comparison benchmark is limited to 2 locations, and the experimental design cannot convincingly isolate the claimed cross-disease transfer mechanism from spatial pooling. These issues are addressable with substantial revision but are too significant for acceptance in the current form.

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>